Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Special Investigation of TALZENNA Capsules - Study on BRCA Mutation-Positive Metastatic Castration-Resistant Prostate Cancer -

NCT06733337 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06733337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06733337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Special Investigation of TALZENNA Capsules - Study on BRCA Mutation-Positive Metastatic Castration-Resistant Prostate Cancer -
Lead sponsor
Pfizer
Phase
Observational
Overall status
Active, not recruiting
Start date
July 11, 2025
Completion date
June 22, 2029
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer